IQVIA Holdings Inc. (IQV) - Company Profile - 2026-04-17
Company Overview
IQVIA Holdings Inc. (IQV) is a U.S.-based healthcare analytics and technology company with approximately 93,000 employees. The company operates in the Healthcare sector, within the Diagnostics & Research industry, and is headquartered in Durham, North Carolina. IQVIA provides clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare clients across the Americas, Europe, Africa, and the Asia-Pacific region. It conducts its business through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers cloud-based applications, implementation services, real-world evidence solutions, and advisory services related to analytics and outsourcing. The Research & Development Solutions segment covers project management, clinical trial support, strategic planning, design services, and central laboratory and biomarker capabilities. The Contract Sales & Medical Solutions segment focuses on health care provider and patient engagement services, plus scientific and medical strategy support for pharmaceutical, biotechnology, device/diagnostic, and consumer health clients. IQVIA was formerly Quintiles IMS Holdings, Inc., and adopted its current name in November 2017.
Business and Operations
IQVIA’s operations are organized around three primary segments, each serving complementary needs of the life sciences and healthcare markets. The Technology & Analytics Solutions segment delivers cloud-based software, data integration, and advanced analytics to enable evidence generation and dissemination for health care decision-making. It also provides country-level performance metrics relating to pharmaceutical sales, prescribing trends, medical treatment patterns, and promotional activity across retail, hospital, and mail-order channels, including granularity at regional, ZIP code, and prescriber levels. The segment supports implementation and consulting services tied to analytics and commercial processes outsourcing. The Research & Development Solutions segment encompasses project management, clinical monitoring, trial support, design and strategic planning, and patient- and site-centric services, along with laboratory capabilities (central lab, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker labs). The Contract Sales & Medical Solutions segment delivers provider and patient engagement services, in addition to medical strategy and scientific services. The company maintains a global footprint spanning the Americas, Europe, Africa, and the Asia-Pacific region to serve pharmaceutical, biotechnology, device/diagnostic, and consumer health clients.
Fundamental Metrics
- Market cap: $29.95B
- Enterprise value: $43.47B
- P/E (trailing): 22.51
- P/E (forward): 12.53
- P/B: 4.60
- P/S: 1.84
- PEG: 0.72
- Profit margin: 8.34%
- Operating margin: 15.17%
- ROE: 21.44%
- ROA: 5.05%
- Debt/Equity: 245.93
- Current ratio: 0.75
- Revenue (TTM): $16.31B
- Revenue growth (YoY): 10.30%
- Earnings growth (YoY): 23.60%
- Free cash flow: $2.22B
- Dividend yield: n/a
- Payout ratio: 0.00%
- Beta: 1.39
Share Structure and Ownership
- Shares outstanding: 167,866,339
- Float: 161,247,243
- Insider held: 1.09%
- Institutional held: 103.37%
- Short ratio (days to cover): 2.81
- Short % of float: 3.11%
Top institutional holders
- Vanguard Group Inc.: 11.58% of shares
- BlackRock Inc.: 8.34% of shares
- Harris Associates L.P.: 6.67% of shares
- State Street Corporation: 4.39% of shares
- Geode Capital Management, LLC: 2.58% of shares
Trading Activity
- Last close: $176.46 on 2026-04-17
- 1-month change: +5.65%
- 3-month change: -26.95%
- Year-to-date (YTD) change: -21.70%
- 1-year change: +24.95%
- 52-week high: $247.05
- 52-week low: $134.65
- [Drawdown](https://aksoycapital.com/glossary/drawdown.html) from 52-week high: -28.57%
- 30-day average volume: 1,472,665
- 90-day average volume: 1,821,370
Recent Price Action
On 2026-04-17, IQVIA closed at $176.46. Over the preceding 1 month, the stock gained 5.65%, while over the prior 3 months it declined by 26.95%. The stock is up 24.95% over the last year but down 21.70% year-to-date. The 52-week range spans $134.65 to $247.05, reflecting a [drawdown](https://aksoycapital.com/glossary/drawdown.html) of 28.57% from the 52-week high. Average trading activity over the last 30 and 90 days shows liquidity in the low-to-mid million-share range on a daily basis.
Strengths
- Diversified operations across three segments (Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions) supporting multiple life sciences workflows.
- Global reach across the Americas, Europe, Africa, and the Asia-Pacific region.
- Scale indicators: revenue of $16.31B (TTM) and free cash flow of $2.22B.
- Profitability and efficiency: ROE of 21.44% and operating margin of 15.17%; profit margin of 8.34%.
- Growth signals: revenue YoY growth of 10.30% and earnings YoY growth of 23.60%.
- Strong institutional ownership profile, with several major holders (e.g., Vanguard Group, BlackRock) controlling meaningful stakes.
- Healthy liquidity indicators on capital markets metrics and a moderate short interest profile (short ratio 2.81 days; short float 3.11%).
Considerations
- Leverage exposure: debt/equity at 245.93, indicating a high level of indebtedness relative to equity.
- Liquidity position: current ratio of 0.75 suggests near-term liquidity pressure relative to short-term obligations.
- Valuation dynamics: trailing P/E at 22.51 vs forward P/E at 12.53, indicating multiple contraction or different market expectations for the near term.
- Price volatility: beta of 1.39 points to higher sensitivity to overall market moves.
- Price performance context: 52-week high of $247.05 vs current close near $176.46 reflects a substantial drawdown from the peak, with a -28.57% drawdown from the high.
- Dividend policy: dividend yield is not applicable and payout ratio is 0.00%, indicating no current dividend payment.
- Market liquidity and flow: 30-day and 90-day average volumes are solid, but liquidity should be monitored in relation to large-cap technology-enabled services bets.
Summary
IQVIA Holdings Inc. operates as a diversified provider of clinical research services, commercial insights, and healthcare intelligence through three segments with a global footprint. As of 2026-04-17, the company reported a market cap of about $29.95 billion, revenue of $16.31 billion (TTM), and free cash flow of $2.22 billion, supported by a strong ROE of 21.44% and a forward P/E of 12.53. Trading metrics show a last close of $176.46, with mixed price performance over the past year and a drawdown from the 52-week high, while liquidity and leverage indicators reflect a current ratio of 0.75 and a debt-to-equity ratio of 245.93. Top institutional holders provide a broad ownership base.